Literature DB >> 24715519

Topological mapping of BRIL reveals a type II orientation and effects of osteogenesis imperfecta mutations on its cellular destination.

Alexa Patoine1, Marie-Hélène Gaumond, Prashant K Jaiswal, François Fassier, Frank Rauch, Pierre Moffatt.   

Abstract

BRIL/IFITM5 is a membrane protein present almost exclusively in osteoblasts, which is believed to adopt a type III (N-out/C-out) topology. Mutations in IFITM5 cause OI type V, but the characteristics of the mutant protein and the mechanism involved are still unknown. The purpose of the current study was to re-assess the topology, localization, and biochemical properties of BRIL and compare it to the OI type V mutant in MC3T3 osteoblasts. Immunofluorescence labeling was performed with antibodies directed against BRIL N- or C-terminus. In intact cells, BRIL labeling was conspicuously detected at the plasma membrane only with the anti-C antibody. Detection of BRIL N-terminus was only possible after cell permeabilization, revealing both plasma membrane and Golgi labeling. Trypsinization of live cells expressing BRIL only cleaved off the C-terminus, confirming that it is a type II protein and that its N-terminus is intracellular. A truncated form of BRIL lacking the last 18 residues did not appear to affect localization, whereas mutation of a single leucine to arginine within the transmembrane segment abolished plasma membrane targeting. BRIL is first targeted to the endoplasmic reticulum as the entry point to the secretory pathway and rapidly traffics to the Golgi via a COPII-dependent pathway. BRIL was found to be palmitoylated and two conserved cysteine residues (C52 and C53) were critical for targeting to the plasma membrane. The OI type V mutant BRIL, having a five residue extension (MALEP) at its N-terminus, presented with exactly the same topological and biochemical characteristics as wild type BRIL. In contrast, the S42 > L mutant BRIL was trapped intracellularly in the Golgi. BRIL proteins and transcripts were equally detected in bone from a patient with OI type V, suggesting that the cause of the disease is a gain of function mediated by a faulty intracellular activity of the mutant BRIL.
© 2014 American Society for Bone and Mineral Research.

Entities:  

Keywords:  BRIL; Golgi; IFITM5; cell surface protein; endoplasmic reticulum; osteoblasts; osteogenesis imperfecta; palmitoylation; type II

Mesh:

Substances:

Year:  2014        PMID: 24715519     DOI: 10.1002/jbmr.2243

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  15 in total

Review 1.  Bone biology: insights from osteogenesis imperfecta and related rare fragility syndromes.

Authors:  Roberta Besio; Chi-Wing Chow; Francesca Tonelli; Joan C Marini; Antonella Forlino
Journal:  FEBS J       Date:  2019-07-05       Impact factor: 5.542

Review 2.  IFITM5 mutations and osteogenesis imperfecta.

Authors:  Nobutaka Hanagata
Journal:  J Bone Miner Metab       Date:  2015-06-02       Impact factor: 2.626

3.  A transgenic mouse model of OI type V supports a neomorphic mechanism of the IFITM5 mutation.

Authors:  Caressa D Lietman; Ronit Marom; Elda Munivez; Terry K Bertin; Ming-Ming Jiang; Yuqing Chen; Brian Dawson; Mary Ann Weis; David Eyre; Brendan Lee
Journal:  J Bone Miner Res       Date:  2015-03       Impact factor: 6.741

Review 4.  Regulation of the trafficking and antiviral activity of IFITM3 by post-translational modifications.

Authors:  Nicholas M Chesarino; Temet M McMichael; Jacob S Yount
Journal:  Future Microbiol       Date:  2014       Impact factor: 3.165

5.  Type V OI primary osteoblasts display increased mineralization despite decreased COL1A1 expression.

Authors:  Adi Reich; Alison S Bae; Aileen M Barnes; Wayne A Cabral; Aleksander Hinek; Jennifer Stimec; Suvimol C Hill; David Chitayat; Joan C Marini
Journal:  J Clin Endocrinol Metab       Date:  2014-11-11       Impact factor: 5.958

6.  Hypermineralization and High Osteocyte Lacunar Density in Osteogenesis Imperfecta Type V Bone Indicate Exuberant Primary Bone Formation.

Authors:  Stéphane Blouin; Nadja Fratzl-Zelman; Francis H Glorieux; Paul Roschger; Klaus Klaushofer; Joan C Marini; Frank Rauch
Journal:  J Bone Miner Res       Date:  2017-06-26       Impact factor: 6.741

7.  Osteogenesis Imperfecta: The Impact of Genotype and Clinical Phenotype on Adiposity and Resting Energy Expenditure.

Authors:  Kaitlin L Ballenger; Nicol Tugarinov; Sara K Talvacchio; Marianne M Knue; An N Dang Do; Mark A Ahlman; James C Reynolds; Jack A Yanovski; Joan C Marini
Journal:  J Clin Endocrinol Metab       Date:  2022-01-01       Impact factor: 5.958

8.  A novel IFITM5 mutation in severe atypical osteogenesis imperfecta type VI impairs osteoblast production of pigment epithelium-derived factor.

Authors:  Charles R Farber; Adi Reich; Aileen M Barnes; Patricia Becerra; Frank Rauch; Wayne A Cabral; Alison Bae; Aaron Quinlan; Francis H Glorieux; Thomas L Clemens; Joan C Marini
Journal:  J Bone Miner Res       Date:  2014-06       Impact factor: 6.741

Review 9.  Osteogenesis Imperfecta: Mechanisms and Signaling Pathways Connecting Classical and Rare OI Types.

Authors:  Milena Jovanovic; Gali Guterman-Ram; Joan C Marini
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

10.  Craniocervical abnormalities in osteogenesis imperfecta type V.

Authors:  K Ludwig; C Seiltgens; A Ibba; N Saran; J A Ouellet; F Glorieux; F Rauch
Journal:  Osteoporos Int       Date:  2021-08-05       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.